Iloprost Zentiva (Iloprost)

Iloprost mimics the natural molecule prostacyclin (PGI2) and activates IP receptors on pulmonary vascular smooth‑muscle cells. This activation raises cyclic‑AMP levels, causing smooth‑muscle relaxation, vasodilation of pulmonary vessels, and inhibition of platelet aggregation, thereby lowering pulmonary arterial pressure.

The dose of Iloprost Zentiva is individualized and set by the prescribing clinician. It is administered by inhalation using a nebulizer, and the frequency and amount are adjusted based on the patient’s response, tolerability, and clinical condition.

Safety data for Iloprost in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Iloprost Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Iloprost is an inhaled prostacyclin analogue, whereas alternatives such as epoprostenol and treprostinil are available for continuous intravenous or subcutaneous infusion. Iloprost offers the advantage of non‑continuous dosing via inhalation, which can reduce systemic side effects, but may require multiple daily administrations compared with continuous infusion options.

Iloprost Zentiva should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight, and extreme temperatures. Do not freeze the product, and keep the vial tightly sealed when not in use.

Iloprost Zentiva is supplied as an inhalation solution. It is delivered using a calibrated nebulizer that generates a fine aerosol for inhalation. The patient inhales the medication through a mouthpiece or mask according to the dosing schedule prescribed by the clinician.

The most serious adverse events to monitor include significant hypotension, pulmonary edema, severe bronchospasm, and bleeding complications. Patients should be observed closely during dose initiation and any time the dose is changed, and they should report any sudden shortness of breath, chest pain, or unusual bleeding.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, in those with severe uncontrolled hypotension, active major bleeding, or recent major cardiovascular events such as myocardial infarction without medical clearance.